17-beta-hydroxysteroid dehydrogenase deficiency overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:
{{SK}} 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency
{{SK}} 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency
==Overview==
==Overview==
'''17-beta-hydroxysteroid dehydrogenase deficiency''' is a rare [[autosomal]] [[recessive]] [[developmental]] [[disorder]] that affects male [[sexual]] [[development]].  Individuals with this condition are genetically male and have [[testes]], but do not produce enough [[testosterone]]. The synthesis of [[testosterones]] is impaired and the levels in the serum is low which disrupts the formation of [[external]] [[male]] [[genitalia]] before [[birth]]. The affected individual is male with [[XY]] [[chromosomes]] with [[phenotype]] [[female]] or [[ambiguous]] [[external]] [[genitalia]] which is the external genitalia do not look clearly male or clearly female , characterized by [[clitoromegaly]], [[posterior]] [[labioscrotal]] fusion and [[perineal]] [[blind]] [[vaginal]] [[pouch]]. [[Testes]] are located in [[inguinal]] or in the [[labioscrotal folds]]. The [[internal]] [[urogenital]] [[tract]] ([[epididymites]], [[vasa deferential]], [[seminal vesicles]], [[ejaculatory ducts]]) is well developed; [[prostate]] and [[Müllerian structures]] are absent. Majority of cases do not present until [[puberty]], at which time [[peripheral]] conversion of [[androgen]] [[precursors]] causes ongoing [[virilization]]. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either [[primary amenorrhea]] or sudden onset of virilization and most of the affected individuals develop male [[secondary sex characteristics]], such as increased [[muscle mass]], [[deepening]] of the [[voice]], and development of [[male]] [[pattern]] body [[hair]]. [[HSD17B3]] gene [[mutations]] result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of [[testosterone]] from [[androstenedione]]. [[Genetic]] [[analysis]] can confirm the [[diagnosis]]. [[Gonadectomy]] is recommended to prevent continuous [[virilization]] if a female [[gender]] [[identity]] is established. The risk of [[testicular]] [[neoplasia]] has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are [[infertile]].
'''17-beta-hydroxysteroid dehydrogenase deficiency''' is a rare [[autosomal]] [[recessive]] [[developmental]] [[disorder]] that affects male [[sexual]] [[development]].  Individuals with this condition are genetically male and have [[testes]], but do not produce enough [[testosterone]]. The synthesis of [[testosterones]] is impaired and the levels in the serum is low which disrupts the formation of [[external]] [[male]] [[genitalia]] before [[birth]]. The affected individual is male with [[XY]] [[chromosomes]] with [[phenotype]] [[female]] or [[ambiguous]] [[external]] [[genitalia]] which is the external genitalia do not look clearly male or clearly female , characterized by [[clitoromegaly]], [[posterior]] [[labioscrotal]] fusion and [[perineal]] [[blind]] [[vaginal]] [[pouch]]. [[Testes]] are located in [[inguinal]] or in the [[labioscrotal folds]]. The [[internal]] [[urogenital]] [[tract]] ([[epididymis]], [[vasa deferential]], [[seminal vesicles]], [[ejaculatory ducts]]) is well developed; [[prostate]] and [[Müllerian structures]] are absent. Majority of cases do not present until [[puberty]], at which time [[peripheral]] conversion of [[androgen]] [[precursors]] causes ongoing [[virilization]]. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either [[primary amenorrhea]] or sudden onset of virilization and most of the affected individuals develop male [[secondary sex characteristics]], such as increased [[muscle mass]], [[deepening]] of the [[voice]], and development of [[male]] [[pattern]] body [[hair]]. [[HSD17B3]] gene [[mutations]] result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of [[testosterone]] from [[androstenedione]]. [[Genetic]] [[analysis]] can confirm the [[diagnosis]]. [[Gonadectomy]] is recommended to prevent continuous [[virilization]] if a female [[gender]] [[identity]] is established. The risk of [[testicular]] [[neoplasia]] has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are [[infertile]].
 
==Historical Perspectives==
==Historical Perspectives==
*17 beta hydroxysteroid dehydrogenase III deficiency is initially described in 1971 by Saez and his colleagues.
*17 beta hydroxysteroid dehydrogenase III deficiency is initially described in 1971 by Saez and his colleagues.

Revision as of 07:42, 7 October 2022

17-beta-hydroxysteroid dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17-beta-hydroxysteroid dehydrogenase deficiency overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17-beta-hydroxysteroid dehydrogenase deficiency overview

CDC on 17-beta-hydroxysteroid dehydrogenase deficiency overview

17-beta-hydroxysteroid dehydrogenase deficiency overview in the news

Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency overview

Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency

Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]

Synonyms and keywords: 17-beta hydroxysteroid dehydrogenase III deficiency, 17-ketosteroid reductase deficiency of testis, 17-KSR deficiency, Neutral 17-beta-hydroxysteroid oxidoreductase deficiency, Male Pseudo hermaphroditism with gynecomastia, Testosterone 17-beta-dehydrogenase deficiency

Overview

17-beta-hydroxysteroid dehydrogenase deficiency is a rare autosomal recessive developmental disorder that affects male sexual development. Individuals with this condition are genetically male and have testes, but do not produce enough testosterone. The synthesis of testosterones is impaired and the levels in the serum is low which disrupts the formation of external male genitalia before birth. The affected individual is male with XY chromosomes with phenotype female or ambiguous external genitalia which is the external genitalia do not look clearly male or clearly female , characterized by clitoromegaly, posterior labioscrotal fusion and perineal blind vaginal pouch. Testes are located in inguinal or in the labioscrotal folds. The internal urogenital tract (epididymis, vasa deferential, seminal vesicles, ejaculatory ducts) is well developed; prostate and Müllerian structures are absent. Majority of cases do not present until puberty, at which time peripheral conversion of androgen precursors causes ongoing virilization. Although some patients with less severe defects are brought up as males, affected males are usually raised as girls. During puberty, the affected patients present with either primary amenorrhea or sudden onset of virilization and most of the affected individuals develop male secondary sex characteristics, such as increased muscle mass, deepening of the voice, and development of male pattern body hair. HSD17B3 gene mutations result in a 17-beta hydroxysteroid dehydrogenase 3 enzyme with decrease or no activity, reducing production of testosterone from androstenedione. Genetic analysis can confirm the diagnosis. Gonadectomy is recommended to prevent continuous virilization if a female gender identity is established. The risk of testicular neoplasia has not been determined, a point which should be discussed if patients choose to transition into a male gender role. All affected people with the disease are infertile.

Historical Perspectives

  • 17 beta hydroxysteroid dehydrogenase III deficiency is initially described in 1971 by Saez and his colleagues.

Classification

  • No sufficient data for classification of 17 beta hydroxysteroid dehydrogenase deficiency.

Pathophysiology

  • 17-beta-hydroxysteroid dehydrogenase deficiency-3 is biochemically characterized by decreased levels of testosterone and increased levels of androstenedione as a result of the defect in conversion of androstenedione into testosterone.

Causes

  • HSD17B3 gene mutation causes 17-beta hydroxysteroid dehydrogenase deficiency results a decrease in testosterones production. The reduction of testosterones affects the development of male reproductive tract which results phenotypically female or ambiguous external genitalia.

Differentiating 17 Beta hydroxysteroid Dehydrogenase Deficiency from Other Diseases

  • 17 beta hydroxysteroid dehydrogenase deficiency should be differentiated from other diseases that cause ambiguous genitalia.

Epidemiology and Demographics

  • Although the precise incidence of 17βHSD-3 deficiency is unknown, a recent study from the Netherlands estimated the incidence around 1 in 147,000 newborns, with a calculated heterozygote frequency of 1 in 135.

Risk Factors

  • The potential risk factor for the development of 17 beta hydroxysteroid dehydrogenase 3 deficiency is positive family history.

Screening

  • There is insufficient evidence to recommend routine screening for 17 alpha-hydroxylase deficiency.

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

  • Majority of affected babies with 17-beta hydroxysteroid dehydrogenase 3 deficiency are born with external genitalia that appear female.

Laboratory Findings

  • Increased serum androstenedione and decreased serum testosterone/androstenedione ratios after hCG stimulation. The definitive diagnosis can be made from Genetic testing.

Molecular Genetic Studies

  • 17 beta hydroxysteroid dehydrogenase deficiency is inherited in an autosomal recessive pattern.

Genotyping

  • 17 beta hydroxysteroid dehydrogenase deficiency is a condition with genotypically male and phenotypically female characteristics. There has been no phenotype to genotype correlation.

Pelvic X ray

  • There are no pelvic x ray finding associated with 17 beta hydroxysteroid dehydrogenase 3 deficiency.

CT

  • There are no CT scan finding associated with 17 beta hydroxysteroid dehydrogenase 3 deficiency.

Ultrasound

  • Ultrasound of abdomen and pelvis showed absence of uterus or vagina.

Other Imaging Findings

Other Diagnostic Studies

  • There is no other diagnostic studies found.

Treatment

Medical Therapy

  • If the diagnosis of 17 beta hydroxysteroid dehydrogenase deficiency is made at birth, gender assignment should be discussed, depending on the expected result of virilization genioplasty.

Primary Prevention

  • There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.

Secondary Prevention

  • There is no known method to prevent 17 beta hydroxysteroid dehydrogenase deficiency.

References

Template:WH Template:WS